HD-OPM Archive
Topics › Infections & vaccines

RSV vaccine Arexvy associated with 25-30% lower dementia risk in observational data

Louis Nervegna · Apr 08, 2026 · ♥ 3 reactions · 0 comments · original Facebook post
Infections & vaccinesBrain health & dementia
AI summary & key facts

A shared summary says Arexvy vaccination was associated with roughly 25-30% lower dementia risk within about 18 months and Shingrix with about 17% lower, with the shared AS01 adjuvant hypothesized as the reason. Observational data only.

#rsvHD #vaccinesHD #dementiaHD #alzheimersHD #shinglesHD

Shared from Kenny Yu · original post

An RSV vaccine may reduce dementia risk

Arexvy (adjuvanted) – may confer additional health benefits beyond preventing RSV infection in older adults. In large observational studies, Arexvy vaccination was associated with roughly a 25–30% reduction in dementia risk within ~18 months. This parallels findings for the shingles vaccine Shingrix (which uses the same AS01 immune adjuvant), observed to reduce dementia incidence by ~17% in similar analyses. Researchers hypothesize that the AS01 adjuvant (present in Arexvy and Shingrix but not in Pfizer’s RSV vaccine Abrysvo) triggers immune pathways that help protect the brain, potentially explaining this cognitive benefit. Additionally, RSV vaccination appears to reduce acute cardiovascular complications in the event of an RSV illness: vaccinated seniors experienced about 60% fewer major adverse cardiovascular events (heart attacks, strokes) during RSV-related hospitalizations compared to unvaccinated individuals.

Evidence for Reduced Dementia Risk with RSV Vaccination

Observational Findings: A 2025 study by University of Oxford researchers (published in npj Vaccines) analyzed electronic health records for over 430,000 older adults to examine dementia outcomes after vaccination. They found a 29% lower risk of being diagnosed with dementia in the 18 months following receipt of GSK’s RSV vaccine (Arexvy) compared to a matched group who received an influenza vaccine instead. This same study also observed an ~18% reduction in dementia risk after the adjuvanted shingles vaccine (Shingrix), and about a 37% reduction in those who had received both vaccines, relative to the flu-vaccinated control group. Notably, the combined effect of RSV + shingles vaccines was not significantly greater than one vaccine alone, suggesting that the cognitive benefit might plateau after one adjuvanted vaccine dose. These results build on prior findings from 2024 (published in Nature Medicine) that Shingrix recipients had a 17% lower 6-year dementia incidence compared to recipients of the older Zostavax shingles vaccine (which lacks an adjuvant). In that “natural experiment” study, over 100,000 people who got Shingrix were compared to similar individuals who had received Zostavax during the 2017 transition to the new vaccine; Shingrix was associated with significantly fewer dementia cases (and also ~23–27% lower dementia risk than in people who received unrelated vaccines like flu or tetanus, indicating a benefit beyond just preventing shingles).

← newer: CNN: high-quality plant-rich diet may prevent cognitive impaolder: Higher natural lithium in tap water linked to lower dementia →